Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axial skeleton, resulting in chronic back pain and stiffness. The key treatment goals for AS include improving signs and symptoms of the disease, improving physical function, preventing disability, and slowing or preventing structural damage. TNF-α inhibitors (AbbVie’s Humira, Amgen’s Enbrel, Janssen’s Remicade and Simponi, UCB’s Cimzia, and infliximab biosimilars) have demonstrated efficacy in reducing disease activity in AS. All approved agents in this class are perceived as highly effective options for patients who require more-potent therapies beyond first-line nonsteroidal anti-inflammatory drugs (NSAIDs). Novartis’s IL-17 inhibitor Cosentyx offers an alternative mechanism of action as the only approved non-TNF biological therapy for AS.


  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AS patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AS patients?
  • How has Cosentyx been integrated into the treatment algorithm?
  • What percentage of AS patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of AS patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States.

Key drugs:  Humira, Enbrel, Remicade, Simponi, Cimzia, Cosentyx, Vimovo, methotrexate.

Related Reports

Axial Spondyloarthritis - Access & Reimbursement - Detailed, Expanded Analysis: Axial Spondyloarthritis (ankylosing Spondylitis And Nonradiographic Axial Spondyloarthritis) - US

The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: the tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen’s Enbrel, AbbVie’s...

View Details

Axial Spondyloarthritis - Unmet Need - Detailed, Expanded Analysis: Ankylosing Spondylitis (US & EU)

In the last 15 years, TNF-α inhibitors (AbbVie’s Humira, Amgen / Pfizer’s Enbrel, Janssen’s Remicade and Simponi, UCB’s Cimz...

View Details

Axial Spondyloarthritis - Current Treatment - Detailed, Expanded Analysis : Treatment Algorithms : Claims Data Analysis : Ankylosing Spondylitis (US)

MARKET OUTLOOKAnkylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the sacroiliac joints and the axi...

View Details